SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

(2014) H. Ma et al.   BLOOD

Pharmacological targeting of  -catenin in normal karyotype acute myeloid leukemia blasts

(2014) E. A. Griffiths et al.   HAEMATOLOGICA

A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma

(2014) Lei Zhong et al.   INTERNATIONAL JOURNAL OF CANCER

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

(2014) W Fiskus et al.   LEUKEMIA

Monoclonal antibody targeting of IL-3 receptor   with CSL362 effectively depletes CML progenitor and stem cells

(2013) E. Nievergall et al.   BLOOD

Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo

(2013) Ling-Ling Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention

(2013) J A McCubrey et al.   LEUKEMIA

Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

(2012) B. Z. Carter et al.   BLOOD

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

(2012) R Swords et al.   LEUKEMIA

FLT3 inhibitors: a story of the old and the new

(2011) Amir Fathi et al.   CURRENT OPINION IN HEMATOLOGY

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

β-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem Cells

(2010) Jenny Yeung et al.   CANCER CELL

WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification

(2010) G. S. Coombs et al.   JOURNAL OF CELL SCIENCE

Drug resistance in mutant FLT3-positive AML

(2010) E Weisberg et al.   ONCOGENE

The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

(2010) Y. Wang et al.   SCIENCE

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

(2009) F. Breitenbuecher et al.   BLOOD

Mechanisms of resistance to FLT3 inhibitors

(2009) S. Haihua Chu et al.   DRUG RESISTANCE UPDATES

A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer

(2009) R Najdi et al.   ONCOGENE

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia

(2008) M. M. Loriaux et al.   BLOOD

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment

(2008) U Mony et al.   LEUKEMIA

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY